Multicentric Castleman's Disease in a Hepatitis C-Positive Intravenous Drug User: A Case Report by D. Y. Talukder, S. N. Delpachitra

“…We report a rare presentation of Castleman's disease in a hepatitis C-positive patient and present a short review of treatments described in other similar case reports and studies. …”
Get full text

Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin by Morris Sherman, Lawrence Cohen, Mary Anne Cooper, Magdy Elkashab, Victor Feinman, David Fletcher, Nigel Girgrah, Jenny Heathcote, Mark Levstik, William B McNaull, David Wong, Florence Wong, Colina Yim

“…Today, combination antiviral therapy with pegylated interferon-alpha and ribavirin (RBV) allows many patients infected with hepatitis C virus (HCV) to achieve a sustained virological response, which is equivalent to cure. …”
Get full text

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary by Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha

“…**Background:** Recent international, randomized, placebo-controlled clinical trials (SPRINT-2; RESPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavirin (RBV) and boceprevir (BOC) was more efficacious than the standard dual therapy of PEG and RBV in treatment of patients chronically infected with genotype 1 hepatitis C virus (HCV) infection. The objective of this study was to evaluate the cost-effectiveness of triple therapy in both treatment-naive and treatment-experienced patients in Hungary. …”
Get full text

Erythropoietin and Hepatitis C Therapy: Useful Adjuvant Therapy but Remember to Treat the Patient and Not Just a Number by Eric M Yoshida, Anne Dar Santos, Nilufar Partovi, Jo-Ann E Ford

Get full text

Epidemiology of chronic kidney disease and the heightened risk of hepatitis C virus infection in low-resource settings by Nuryati Anik, Budi Setiawan, Catur Wijayanti

Subjects: Get full text

Hepatitis C Worldwide and in Brazil: Silent Epidemic—Data on Disease including Incidence, Transmission, Prevention, and Treatment by Iara Fabricia Kretzer, Andrea do Livramento, Joel da Cunha, Sabrina Gonçalves, Iraci Tosin, Celso Spada, Aricio Treitinger

“…Hepatitis C virus (HCV) is endemic worldwide and according to the World Health Organization (WHO), there are about 150 million chronic carriers worldwide. …”
Get full text

Computational design of multi-epitope vaccine against Hepatitis C Virus infection using immunoinformatics techniques. by Sara Zubair, Fahed Parvaiz, Turki Abualait, Khalid Al-Regaiey, Tasneem Anwar, Mahnoor Zafar, Imdad Kaleem, Shahid Bashir

“…Hepatitis C Virus (HCV) is a blood borne pathogen that affects around 200 million individuals worldwide. …”
Get full text

Inflammasome Genes’ Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment by Shady Z. K. Estfanous, Sahar A. Ali, Sameh M. Seif, Sameh H. A. Soror, Dalia H. A. Abdelaziz

“…Chronic inflammation is a pivotal contributor to the liver damage mediated by hepatitis C virus (HCV). The NOD-like receptor, pyrin domain-containing 3 (NLRP3) inflammasome is activated by HCV in both hepatocytes and Kupffer cells. …”
Get full text

Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis by Sarah R. Donaldson, Andrew Radley, John F. Dillon

Subjects: “…Hepatitis C…”
Get full text

Seroprevalence of hepatitis B and C virus among a group of hemophilia patients in Kurdistan Region, Iraq by Salih A. Hama

Subjects: Get full text

Evaluation of liver fibrosis in HCV-infected patients using two-dimensional shear-wave elastography (2D-SWE) before and after antiviral treatment by Inglot Marcin, Pozowski Patryk, Misiak Paula, Fleischer-Stępniewska Katarzyna, Lewandowski Łukasz, Bilski Mateusz, Zaleska-Dorobisz Urszula

Subjects: Get full text

Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey by M. Assem, M. Yousri

“…Pentoxifylline and vitamin E can ameliorate RBV-associated haemolysis; improve compliance and virologic clearance when combined with the standard antiviral therapy in patients with chronic hepatitis C.…”
Get full text

Potensi Kombinasi Naringenin-Liposom Sebagai Anti-Viral dan Anti-Fibrotik dalam Penatalaksanaan Hepatitis C by Ida AyuWidya Anjani, I Wayan Windi Artha, Ni Made Ari Purwaningrum, Sinta Wiranata, I Gede Putu Supadmanaba, Desak Made Wihandani

“…Naringenin berpotensi sebagai modalitas anti-viral dan anti-fibrotik pada penatalaksanaan hepatitis C. Sebagai anti-viral, naringenin mampu menghambat sekresi virus hepatitis C sebanyak 80% melalui penghambatan aktivitas MTP, ACAT2, dan HMGR. …”
Get full text

Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients by Ioannis S. Elefsiniotis, Christos Pavlidis, Elena Vezali, Theodoros Mariolis-Sapsakos, Sotirios Koutsounas, George Saroglou

“…To evaluate the impact of hepatitis B core antibody (anti-HBc) seropositivity in sustained virological response (SVR) rates in treatment-naïve, chronic hepatitis C (CHC) patients with high pretreatment viral load (>800000 IU/mL). …”
Get full text

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis by Yinan Yao, Ming Yue, Jie Wang, Hongbo Chen, Mei Liu, Feng Zang, Jun Li, Yun Zhang, Peng Huang, Rongbin Yu

“…It is urgent for patients with hepatitis C virus (HCV) infection to find a safe, effective, and interferon-free regimen to optimize therapy. …”
Get full text

Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study by Ying Chen, Yun Bao, Mengxia Yan, Huajie Jin, Kaijie Yao, Chi Zhang, Wen Li, Bin Wu

Subjects: “…Hepatitis C virus…”
Get full text

Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs by Ye. N. German, M. V. Mayevskaya, O. I. Andreytseva, V. T. Ivashkin, A. V. Chzhao, A. G. Serova, G. V. Mikhaylovskaya, I. Yu. Pirogova

“…To study the role of serological markers of hepatitis B virus infection: antibodies to hepatitis B virus cor-antigen (anti-HВcor IgG) in progressing liver damage at patients with persistent hepatitis C virus infection.Material and methods. For the first time in the large group of patients (2934) significant prevalence of serological markers of hepatitis B and C viruses among patients of versatile clinic was demonstrated.Results. …”
Get full text

Hepatitis C Virus Clearance after Discontinuation of Pegylated Interferon Alpha-2a Monotherapy in a Child by Takeshi Endo, Koichi Ito, Tokio Sugiura, Kenji Goto

“…The present patient was a 4-year-old boy. His hepatitis C virus genotype was 2a, and his viral load was high (1400,000 U/mL). …”
Get full text

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy by M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin

Subjects: “…chronic hepatitis c…”
Get full text

Factors Associated with the Progression of Fibrosis on Liver Biopsy in Alaska Native and American Indian Persons with Chronic Hepatitis C by Stephen E Livingston, Heike Deubner, Dana L Bruden, Brian J McMahon, Chriss E Homan, Lisa J Townshend-Bulson, Michael G Bruce, Thomas W Hennessy, James L Williams, David R Gretch

“…BACKGROUND: Various factors influence the development and rate of fibrosis progression in chronic hepatitis C virus (HCV) infection.…”
Get full text